Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

NCT00440973 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped contract issues

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Bevacizumab
DRUG: Interleukin-2

Sponsor

The Methodist Hospital Research Institute

Collaborators

[object Object]